Product overview

  • Name
    1-EBIO
  • Short description
    Epithelial KCa channel activator. Promotes ESC differentiation into cardiomyocytes.
  • Biological description
    Epithelial KCa channel activator (K0.5 = 84 µM for KCa3.1 channels). Hyperpolarises aortic valve endothelial cells to the same extent as acetylcholine. Also promotes embroyonic stem cell (ESC) differentiation into cardiomyocytes. Displays vasodilation and anticonvulsant properties.
  • Biological action
    Activator
  • Purity
    >99%
  • Our products in action

Properties

  • Chemical name
    1-Ethyl-2-benzimidazolinone
  • Molecular Weight
    162.19
  • Chemical structure
    1-EBIO  [10045-45-1]
  • Molecular Formula
    C9H10N2O
  • CAS Number
    10045-45-1
  • PubChem identifier
    82320
  • SMILES
    CCN1C2=CC=CC=C2NC1=O
  • InChi
    InChI=1S/C9H10N2O/c1-2-11-8-6-4-3-5-7(8)10-9(11)12/h3-6H,2H2,1H3,(H,10,12)
  • InChiKey
    CXUCKELNYMZTRT-UHFFFAOYSA-N
  • MDL number
    MFCD00005715

Storing and Using Your Product

  • Storage instructions
    Room temperature
  • Solubility overview
    Soluble in DMSO (100mM) and in ethanol (100mM)
  • Important
    This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.

References for 1-EBIO

  • 1-Ethyl-2-benzimidazolinone stimulates endothelial K(Ca) channels and nitric oxide formation in rat mesenteric vessels.

    Adeagbo AS (1999) Eur J Pharmacol 379(2-3) : 151-9.
    PubMedID: 10497901
  • Pharmacological activation of cloned intermediate- and small-conductance Ca(2+)-activated K(+) channels.

    Syme CA et al (2000) Am J Physiol Cell Physiol 278(3) : C570-81.
    PubMedID: 10712246
  • In vivo characterisation of the small-conductance KCa (SK) channel activator 1-ethyl-2-benzimidazolinone (1-EBIO) as a potential anticonvulsant.

    Anderson NJ et al (2006) Eur J Pharmacol 546(1-3) : 48-53.
    PubMedID: 16925994
  • Reduced hyperpolarization in endothelial cells of rabbit aortic valve following chronic nitroglycerine administration.

    Kusama N et al (2005) Br J Pharmacol 146(4) : 487-97.
    PubMedID: 16056232